Skip to Main Content

Advertisement

Skip Nav Destination

The AACR appreciates that the COVID-19 pandemic might well be impacting your health, the work ongoing in your labs, and may be placing you on the front lines to fight and care for those affected. In support of your research, particularly as it relates to COVID-19, the AACR has undertaken a number of initiatives, including the creation of a COVID-19 Task Force, the hosting of special sessions on COVID-19 and cancer at the AACR Virtual Annual Meeting, a special virtual conference that focused on COVID-19 and cancer, and this COVID-19 & Cancer Resource Center. This online resource brings together content related to COVID-19 from across the AACR journals as soon as it is published—and it is free to access for the duration of the pandemic.

AACR Letter to Congress

AACR Calls on Congress to Take Immediate Action Against COVID-19 and Protect Patients with Cancer During the Pandemic

Research Articles

Impact of Exercise on Susceptibility and Severity of COVID-19 in Patients with Cancer: A Retrospective Study

PHE Extends Telehealth Services—for Now

Patients recently treated for B-lymphoid malignancies show increased risk of severe COVID-19: a CCC19 registry analysis

The polarity and specificity of antiviral T lymphocyte responses determine susceptibility to SARS-CoV-2 infection in cancer patients and healthy individuals.

CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Pre-Established Immunity

Longitudinal SARS-CoV-2 mRNA Vaccine-Induced Humoral Immune Responses in Patients with Cancer

Bemcentinib and Gilteritinib Inhibit Cell Growth and Impair the Endo-Lysosomal and Autophagy Systems in an AXL-Independent Manner

Prolonged SARS-CoV-2 infection in patients with lymphoid malignancies

Characteristics and Outcomes of Over 300,000 Patients with COVID-19 and History of Cancer in the United States and Spain

Immunogenicity and safety of COVID-19 vaccine BNT162b2 for patients with solid cancer: a large cohort prospective study from a single institution.

Excess Mortality in a Nationwide Cohort of Cancer Patients during the Initial Phase of the COVID-19 Pandemic in Belgium

Predictors of Humoral Response to SARS-CoV-2 Vaccination after Hematopoietic Cell Transplantation and CAR T Cell Therapy

Disease and therapy-specific impact on humoral immune responses to COVID-19 vaccination in hematologic malignancies

Six Month Efficacy and Toxicity Profile of BNT162b2 Vaccine in Cancer Patients with Solid Tumors

Preexisting and post-COVID-19 immune responses to SARS-CoV-2 in cancer patients

COVID-19 disruptions to endoscopic surveillance in Lynch syndrome

Priority COVID-19 vaccination for patients with cancer while vaccine supply is limited

Cancer and COVID-19: On the Quest for Effective Vaccines

Viral Immunity and Vaccines in Hematologic Malignancies: Implications for COVID-19

Examining COVID-19 Preventive Behaviors among Cancer Survivors in the United States: An Analysis of the COVID-19 Impact Survey

Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer

COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers

Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study

Impact of PD-1 Blockade on Severity of COVID-19 in Patients with Lung Cancers

Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System

Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak

 

Perspectives & Commentaries

Vive la Résistance: T-cell Immunity in the Protection against SARS-CoV-2 Infection

Special Report: AACR Report on the Impact of COVID-19 on Cancer Research and Patient Care

Learning through a Pandemic: The Current State of Knowledge on COVID-19 and Cancer

How to provide the needed protection from COVID-19 to patients with hematologic malignancies

Impaired CD4 T-cell Response to SARS-CoV-2: Rationale for PD-1 Blockade in Patients with Cancer and COVID-19?

Rethinking Cancer Clinical Trial Conduct Induced by COVID-19: An Academic Center, Industry, Government, and Regulatory Agency Perspective

A Neoadjuvant Chemotherapy Trial for Early Breast Cancer is Impacted by COVID-19: Addressing Vaccination and Cancer Trials Through Education, Equity, and Outcomes

Q&A: Ned Sharpless on COVID-19 and Cancer Prevention

Vascular normalization to improve treatment of COVID-19: Lessons from treatment of cancer

Is COVID-19–Induced Platelet Activation a Cause of Concern for Patients with Cancer?

How did we get a COVID-19 vaccine in less than one year?

At the Crossroads: COVID-19 and Immune Checkpoint Blockade for Cancer

Is COVID-19 - induced platelet activation a cause of concern for cancer patients?

Similarities in Risk for COVID-19 and Cancer Disparities

Don't Compromise Myeloma Care Due to COVID-19 Pandemic!

COVID-19, Cancer Care and Prevention

Disparities in Cancer Prevention in the COVID-19 Era

The Paradoxical Effects of COVID-19 on Cancer Care: Current Context and Potential Lasting Impacts

Cancer Research: The Lessons to Learn from COVID-19

COVID-19 Testing in Patients with Cancer: Does One Size Fit All?

Immune-Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era

The World of Clinical Trial Development Post-Covid-19: Lessons Learned from a Global Pandemic.

The Era of COVID-19 and the Rise of Science Collectivism in Cancer Research

The COronavirus Pandemic Epidemiology (COPE) Consortium: A Call to Action

BTK Inhibitors in Cancer Patients with COVID-19: “The Winner Will be the One Who Controls That Chaos” (Napoleon Bonaparte)

Adapting to a Pandemic — Conducting Oncology Trials during the SARS-CoV-2 Pandemic

 

Webinars

AACR Virtual Journal Club: Blood Cancer Discovery, Direct and Indirect Impact of COVID-19 on Multiple Myeloma Patients

 

News

Top COVID-19 Prognostic Factors Identified

Pandemic Provides Rapid Test of Telehealth

Navigating Cancer Care in the COVID-19 Era

Case Builds for Booster Shots for People with Cancer

Cancer Therapy Doesn't Diminish Vaccine Efficacy

COVID-19 Use Causes Tocilizumab Shortage

More Cancer Centers Requiring COVID Shots for Workers

COVID-19 Vaccines Complicate Breast Screening

Blood Cancers Diminish Response to COVID-19 Vaccine

How Cancer Vaccine Tech Shaped COVID Response

COVID-19 Prolonged in Patients with Cancer

Survival Factors ID'd for Patients with Blood Cancer + COVID-19

Repurposing Cancer Drugs for COVID-19

Q&A: Solange Peters on COVID-19, Cancer Intersection; Immunotherapy Biomarkers

ICI Impact on COVID-19 Severity Modest at Best

COVID-19 Challenges Status Quo for Cancer Care

COVID-19 Delays Cancer Screenings

Registries Offer Insights on COVID-19–Cancer Connection

COVID-19 Hits Cancer Research Funding

Cytokine Storm Drugs Move from CAR T to COVID-19

Clinical Research Slows as COVID-19 Surges

IL6 Blockade Reverses Anemia in AML Mice

COVID-19 More Frequent, Severe in Cancer Patients

Cancer Care Goes Virtual in Response to COVID-19

Cancer Labs Pivot to Battle COVID-19

COVID-19 Challenges Basic Researchers

 

Reviews

Immune-guided therapy of COVID-19

Repurposing of anticancer drugs expands possibilities for antiviral and anti-inflammatory discovery in COVID-19

Relevance of the Bruton Tyrosine Kinase (BTK) as a target for COVID-19 therapy

Harnessing CAR T Cell Insights to Develop Treatments for Hyperinflammatory Responses in COVID-19 patients

TMPRSS2 and COVID-19: Serendipity or Opportunity for Intervention?

 

Close Modal

or Create an Account

Close Modal
Close Modal